# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0150 |
| Population Package | PP-0150 |
| Title | CDH1 Germline Pathogenic Variants |
| Version | 1.0.0 |
| Status | PASS |

---

# 1. Content QA

| Criterion | Result |
|---|---|
| Single gene-level educational question | PASS |
| CDH1 clearly defined | PASS |
| Germline concept clearly defined | PASS |
| Pathogenicity explained | PASS |
| Variant spectrum included | PASS |
| VUS boundary included | PASS |
| Genotype–phenotype uncertainty included | PASS |
| Cancer-risk implications included | PASS |
| Unexpected findings included | PASS |
| Family implications included | PASS |
| No unnecessary mutation catalogue | PASS |
| No duplication of full HDGC management | PASS |

---

# 2. Clinical QA

| Criterion | Result |
|---|---|
| NCI HDGC PDQ prioritized | PASS |
| NCI Genetics of Gastric Cancer PDQ used | PASS |
| NCI Cancer Genetics Risk Assessment source used | PASS |
| CDH1/E-cadherin relationship accurate | PASS |
| Germline vs somatic distinction accurate | PASS |
| Pathogenic vs VUS distinction accurate | PASS |
| Variant classes appropriately framed | PASS |
| Genotype–phenotype uncertainty preserved | PASS |
| Cancer-risk implications accurately framed | PASS |
| Unexpected CDH1 findings appropriately framed | PASS |
| Cascade-testing concept accurate | PASS |
| No individualized risk prediction | PASS |
| No individualized management recommendation | PASS |

---

# 3. Educational QA

| Criterion | Result |
|---|---|
| Plain-language framing | PASS |
| Technical concepts proportionate to audience | PASS |
| Gene-level scope maintained | PASS |
| Patient-important implications emphasized | PASS |
| Pathogenicity explained without laboratory overload | PASS |
| VUS misconception directly addressed | PASS |
| Germline/somatic misconception directly addressed | PASS |
| Risk uncertainty clearly communicated | PASS |
| No deterministic language | PASS |

---

# 4. Governance QA

| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Gold Specification v1.0 followed | PASS |
| Approved Decision Batch implemented | PASS |
| Scope not reopened after approval | PASS |
| Evidence traceability documented | PASS |
| Knowledge Graph documented | PASS |
| Boundary/overlap declared | PASS |
| Versioning complete | PASS |

---

# 5. Boundary / Overlap QA

## PP-0149 — HDGC

PP-0149 owns the syndrome, cancer risks and clinical management.

PP-0150 owns CDH1 gene/variant interpretation concepts.

**Result: PASS**

## PP-0015 — Hereditary Gastric Cancer

PP-0015 owns the broader hereditary gastric-cancer landscape.

PP-0150 remains gene-specific.

**Result: PASS**

## PP-0016 — Genetic Testing

PP-0016 owns the general testing framework.

PP-0150 explains the CDH1-specific meaning of a result.

**Result: PASS**

## Variant Interpretation

Detailed variant classification methodology is delegated.

PP-0150 only provides patient-facing interpretation concepts.

**Result: PASS**

## PP-0110 / PP-0113 / PP-0114

These belong to the somatic/tumor molecular branch.

PP-0150 is explicitly germline.

**Result: PASS**

---

# 6. Clinical Safety QA

| Safety Item | Result |
|---|---|
| No personal diagnosis | PASS |
| No individual variant interpretation | PASS |
| No individual cancer-risk calculation | PASS |
| No individualized surgery recommendation | PASS |
| No individualized surveillance schedule | PASS |
| No treatment recommendation | PASS |
| VUS not treated as pathogenic | PASS |
| Pathogenic result not equated with current cancer | PASS |
| Genotype not presented as deterministic | PASS |
| Specialist interpretation/counseling boundary preserved | PASS |

---

# 7. Evidence Traceability QA

Primary:

- NCI Hereditary Diffuse Gastric Cancer (PDQ®)

Supporting:

- NCI Genetics of Gastric Cancer (PDQ®)
- NCI Cancer Genetics Risk Assessment and Counseling (PDQ®)
- relevant project guideline materials

The central gene-level claims are supported by direct source material.

Evidence limitations around genotype–phenotype prediction and individual risk are explicitly retained.

---

# 8. Scope Integrity QA

### Correctly Included

- CDH1
- E-cadherin
- germline pathogenic variants
- variant spectrum
- pathogenicity
- VUS
- genotype–phenotype uncertainty
- meaning of positive result
- unexpected findings
- family implications

### Correctly Excluded

- complete HDGC syndrome management
- RRTG
- detailed endoscopy
- detailed breast surveillance
- general genetic-testing methodology
- detailed ACMG scoring
- detailed NGS
- detailed variant databases
- detailed genetic counseling

**Result: PASS**

---

# 9. Knowledge Graph QA

### Parent / Clinical Context

PP-0149 — Hereditary Diffuse Gastric Cancer

### Broader Framework

PP-0015 — Hereditary Gastric Cancer

PP-0016 — Genetic Testing

### Delegated

Variant Interpretation

Genetic Counseling

### Separate Somatic Branch

PP-0110 — Somatic Genetic Testing

PP-0113 — Molecular Tumor Profiling

PP-0114 — Genomic Biomarkers in Gastric Cancer

**Result: PASS**

---

# 10. Gold Artifact QA

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

---

# 11. Final QA Decision

# PASS

PP-0150 satisfies the locked Gold Population Package requirements.

The package maintains a clear hierarchy:

**Hereditary Gastric Cancer**
→ **HDGC syndrome**
→ **CDH1 germline pathogenic variant**

while preserving separation from:

**Genetic Testing**
→ **Variant Interpretation**

and:

**Somatic Genetic Testing**
→ **Molecular Tumor Profiling**
→ **Genomic Biomarkers**

---

# Final Status

**APPROVED — GOLD / QA PASS**
